source
- Epicrispr and Infinimmune secure $165 million in venture funding for epigenetic and antibody programsEpicrispr Biotechnologies announced a $90 million Series C round to push its epigenetic therapy program for facioscapulohumeral muscular dystrophy (FSHD). The lead candidate, EPI-321, is in a firs…
- Former Legend Biotech chief Ying Huang named CEO of K2, targets $250 million Series A to license Asian assetsYing Huang spent the past seven years building one of the leading cancer cell‑therapy companies before stepping down as CEO of Legend Biotech. Weeks after announcing his departure, Huang has taken…